The clinical pharmacology of methotrexate.

[1]  J. Grant.  Reversed Rotation of the Intestine with Encapsulating Peritonitis* , 1940, British medical journal.

[2]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[3]  R D SULLIVAN,et al.  Antimetabolite‐metabolite combination cancer chemotherapy. Effects of intra‐arterial methotrexate—intramuscular citrovorum factor therapy in human cancer , 1959, Cancer.

[4]  W. C. Werkheiser.  Specific Binding of 4-Amino Folic Acid Analogues by Folic Acid Reductase , 1961 .

[5]  G. A. Fischer.  Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells. , 1962, Biochemical pharmacology.

[6]  E. Henderson,et al.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. , 1965, Cancer research.

[7]  I. Djerassi,et al.  Long-Term Remissions in Childhood Acute Leukemia , 1966 .

[8]  S. Farber,et al.  Continuous infusion of methotrexate in children with acute leukemia , 1967, Cancer.

[9]  D. Williams,et al.  A colorimetric assay system for tetrahydrofolate dehydrogenase. , 1968, Biochemical pharmacology.

[10]  T. Hall,et al.  Triamterene-induced elevation of dihydrofolate reductase activity in human leukocytes. , 1968, Biochemical pharmacology.

[11]  D. Hutchison,et al.  On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia. , 1968, Cancer research.

[12]  V. Oliverio,et al.  Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. , 1968, The Journal of biological chemistry.

[13]  E. Henderson,et al.  The effect of organic acids on renal clearance of methotrexate in man , 1969, Clinical pharmacology and therapeutics.

[14]  S. Comaish,et al.  Site of action of methotrexate in psoriasis. , 1969, Archives of dermatology.

[15]  J. Bertino,et al.  Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". , 1970, Cancer research.

[16]  P. Ernst,et al.  Perturbation of generation cycle of human leukemic myeloblasts in vivo by methotrexate. , 1971, Blood.

[17]  I. Goldman.  THE CHARACTERISTICS OF THE MEMBRANE TRANSPORT OF AMETHOPTERIN AND THE NATURALLY OCCURRING FOLATES , 1971, Annals of the New York Academy of Sciences.

[18]  V. Oliverio,et al.  Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid. , 1972, Biochemical pharmacology.

[19]  J. Bertino,et al.  Enzymatic Cleavage of Methotrexate provides a Method for Prevention of Drug Toxicity , 1972, Nature.

[20]  A. V. Hoffbrand,et al.  Unbalanced Deoxyribonucleotide Synthesis Caused by Methotrexate , 1972, British medical journal.

[21]  I. Goldman,et al.  Characteristics of the vincristine-induced augmentation of methotrexate uptake in Ehrlich ascites tumor cells. , 1973, The Journal of biological chemistry.

[22]  R. Jackson,et al.  Studies with a mathematical model of folate metabolism. , 1973, Archives of biochemistry and biophysics.

[23]  B. Chabner,et al.  Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. , 1973, The Journal of clinical investigation.

[24]  J. Bertino,et al.  Improved therapeutic index of methotrexate with "leucovorin rescue". , 1973, Cancer research.

[25]  B. Hoogstraten,et al.  Effect of route of administration and effusions on methotrexate pharmacokinetics. , 1974, Cancer research.

[26]  R. Cailleau,et al.  Tissue culture studies on pleural effusions from breast carcinoma patients. , 1974, Cancer research.

[27]  F. M. Huennekens,et al.  Effects of sulfhydryl inhibitors upon transport of folate compounds into L1210 cells. , 1974, Biochemical pharmacology.

[28]  Goldman Id.  The Mechanism of Action of Methotrexate: I. Interaction with a Low-Affinity Intracellular Site Required for Maximum Inhibition of Deoxyribonucleic Acid Synthesis in L-Cell Mouse Fibroblasts , 1974 .

[29]  B. Hoogstraten,et al.  Pharmacokinetics of methotrexate , 1973, Clinical pharmacology and therapeutics.

[30]  H. Weiss,et al.  Neurotoxicity of commonly used antineoplastic agents (first of two parts). , 1974, The New England journal of medicine.

[31]  N. Jaffe,et al.  Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. , 1974, The New England journal of medicine.

[32]  N. Jaffe.  Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors. , 1974, Cancer chemotherapy reports.

[33]  I. Goldman.  Analysis of the cytotoxic determinants for methotrexate (NSC 740): a role for 'free' intracellular drug , 1975 .

[34]  M. Berman,et al.  Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. , 1975, Cancer chemotherapy reports.

[35]  P. Schein,et al.  Immunosuppressive and cytotoxic chemotherapy: long-term complications. , 1975, Annals of internal medicine.

[36]  S. Waxman,et al.  Interaction of chemotherapeutic agents with methotrexate and 5-fluorouracil and its effect on de novo DNA synthesis. , 1975, Cancer research.

[37]  R. Capizzi.  SCHEDULE-DEPENDENT SYNERGISM AND ANTAGONISM BETWEEN METHOTREXATE AND ASPARAGINASE* , 1975 .

[38]  W. Shapiro,et al.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. , 1975, The New England journal of medicine.

[39]  R. Moran,et al.  Effects of allopurinol on the therapeutic efficacy of methotrexate. , 1975, Cancer research.

[40]  J. White,et al.  The mechanism of action of methotrexate. III. Requirement of free intracellular methotrexate for maximal suppression of (14C)formate incorporation into nucleic acids and protein. , 1975, Molecular pharmacology.

[41]  E. Frei,et al.  The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects , 1975, Nature.

[42]  C. N. Coleman,et al.  The clinical pharmacology of antineoplastic agents (second of two parts). , 1975, The New England journal of medicine.

[43]  C. N. Coleman,et al.  The Clinical Pharmacology of Antineoplastic Agents , 1975 .

[44]  Martin H. Cohen,et al.  Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients , 1976, Cancer.

[45]  C. Putman,et al.  METHOTREXATE-INDUCED PNEUMONITIS , 1976, Medicine.

[46]  B. Chabner,et al.  7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. , 1976, The Journal of clinical investigation.

[47]  B. Chabner,et al.  The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. , 1976, Cancer research.

[48]  H. Mouridsen,et al.  The pharmacokinetics of cyclophosphamide in man following treatment with methotrexate. , 2009, Acta pharmacologica et toxicologica.

[49]  S. Jacobs,et al.  Accumulation of methotrexate diglutamate in human liver during methotrexate therapy. , 1977, Biochemical pharmacology.

[50]  J. Bull,et al.  The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. , 1977, Cancer research.

[51]  G. Browman,et al.  Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines. , 1977, Chemico-biological interactions.

[52]  D. Rosenthal,et al.  High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. , 1977, Blood.

[53]  B. Chabner,et al.  Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity. , 1977, Cancer treatment reports.

[54]  D. Zaharko,et al.  Relative biochemical aspects of low and high doses of methotrexate in mice. , 1977, Cancer research.

[55]  S. Rosenberg,et al.  Methotrexate and hemodialysis. , 1977, Annals of internal medicine.

[56]  Antifolates: in vivo kinetic considerations. , 1977 .

[57]  Effects of methotrexate on cellular metabolism: Some critical elements in the drug cell interaction , 1977 .

[58]  W. Ensminger,et al.  The prevention of methotrexate toxicity by thymidine infusions in humans. , 1977, Cancer research.

[59]  A. Freeman,et al.  High-dose methotrexate in acute lymphocytic leukemia. , 1977, Cancer treatment reports.

[60]  J. Rasey,et al.  The effect of photon irradiation on blood‐brain barrier permeability to methotrexate in mice , 1977, Cancer.

[61]  D. Talbot,et al.  Some observations on the reversibility of methotrexate toxicity in normal proliferating tissues. , 1977, Journal of the National Cancer Institute.

[62]  S. Rosenberg,et al.  Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. , 1977, The New England journal of medicine.

[63]  B. Chabner,et al.  Dose-dependent metabolism of methotrexate in man and rhesus monkeys. , 1977, Cancer treatment reports.

[64]  Bondy Pk,et al.  Some observations on the human pharmacology of methotrexate. , 1977 .

[65]  G. Weinstein.  Drugs Five Years Later: Methotrexate , 1977 .

[66]  Frei E rd,et al.  Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. , 1977 .

[67]  V. Whitehead.  Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells. , 1977, Cancer research.

[68]  Antimetabolites in the central nervous system. , 1977 .

[69]  W. Strum.  A pH-dependent, carrier-mediated transport system for the folate analog, amethopterin, in rat jejunum. , 1977, The Journal of pharmacology and experimental therapeutics.

[70]  D. Rosenblatt,et al.  Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells. , 1978, Molecular pharmacology.

[71]  S. Howell,et al.  Hemodialysis and enzymatic cleavage of methotrexate in man. , 1978, European journal of cancer.

[72]  S. Howell,et al.  Thymidine rescue of high-dose methotrexate in humans. , 1978, Cancer research.

[73]  C. Pratt,et al.  Effect of pleural effusion on high‐dose methotrexate kinetics , 1978, Clinical pharmacology and therapeutics.

[74]  R. Benjamin,et al.  Refractory acute leukaemia in adults treated with sequential colaspase and high-dose methotrexate , 1978, British medical journal.

[75]  R. Donehower,et al.  Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells. , 1978, Cancer research.

[76]  A. Goldin.  Studies with high-dose methotrexate--historical background. , 1978, Cancer treatment reports.

[77]  G. Grindey,et al.  Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine. , 1978, Cancer research.

[78]  Jacobsen Sa,et al.  Phase I trial of high-dose methotrexate with modified citrovorum factor rescue. , 1978 .

[79]  H. Kaplan,et al.  A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. , 1979, Cancer research.

[80]  L. Irwin,et al.  Anaphylactic reaction to high-dose methotrexate. , 1979, Cancer treatment reports.

[81]  J. White,et al.  Formation of methotrexate polyglutamates in rat hepatocytes. , 1979, Cancer research.

[82]  A. Nyfors,et al.  Cytogenetic effects of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test. , 1979, Mutation research.

[83]  S. Hilliard,et al.  Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells. , 1979, Cancer research.

[84]  R. Donehower,et al.  Presence of 2,4‐diamino‐N10‐methylpteroic acid after high‐dose methotrexate , 1979, Clinical pharmacology and therapeutics.

[85]  J. White,et al.  Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. , 1979, Cancer research.

[86]  F. Sirotnak,et al.  Schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia. , 1979, Cancer treatment reports.

[87]  C. Heidelberger,et al.  Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[88]  S. Howell,et al.  Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate. , 1979, Cancer research.

[89]  W. M. Shehata,et al.  The enhancement effect of irradiation by methotrexate. Report of three complications , 1980, Cancer.

[90]  R. Schimke.  Gene amplification and drug resistance. , 1980, Scientific American.

[91]  J. Goldie,et al.  A methotrexate insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells. , 1980, European journal of cancer.

[92]  J. White,et al.  Effects of 2,4-dinitrophenol and other metabolic inhibitors on the bidirectional carrier fluxes, net transport, and intracellular binding of methotrexate in Ehrlich ascites tumor cells. , 1980, Cancer research.

[93]  S. Waxman,et al.  Limited effectiveness of in vitro high-dose methotrexate and leucovorin to overcome resistance in L1210 leukemia cells with elevations of dihydrofolate reductase. , 1980, European journal of cancer.

[94]  M. Wick,et al.  Natural resistance to methotrexate in human melanomas. , 1980, The Journal of investigative dermatology.

[95]  C. R. Pinkerton,et al.  Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukaemia. , 1980, British Journal of Cancer.

[96]  Effect of gentamicin and irradiation on the toxicity of high-dose methotrexate in rats. , 1980 .

[97]  R. Bast,et al.  High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. , 1980, The American journal of medicine.

[98]  W. Flintoff,et al.  Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. , 1980, Biochemistry.

[99]  C. R. Pinkerton,et al.  CAN FOOD INFLUENCE THE ABSORPTION OF METHOTREXATE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKÆMIA? , 1980, The Lancet.

[100]  J. Mulder,et al.  Cell kinetic factors, single drugs and combination. , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[101]  J. Lankelma,et al.  Change in Transfer Rate of Methotrexate from Spinal Fluid to Plasma during Intrathecal Therapy in Children and Adults , 1980, Clinical pharmacokinetics.

[102]  H. Pinedo,et al.  Effect of methotrexate on 5-phosphoribosyl 1-pyrophosphate levels in L1210 leukemia cells in vitro. , 1980, Cancer research.

[103]  J. Galivan.  Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. , 1980, Molecular pharmacology.

[104]  S. Howell,et al.  Achievement of long duration methotrexate exposure with concurrent low dose thymidine protection: influence of methotrexate pharmacokinetics. , 1980, European journal of cancer.

[105]  R. Schilsky,et al.  Methotrexate polyglutamate synthesis by cultured human breast cancer cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[106]  J. Lankelma,et al.  The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. , 1980, Cancer letters.

[107]  F. M. Huennekens,et al.  Inhibition of dihydrofolate reductase by methotrexate: a new look at an old problem. , 1980, Advances in enzyme regulation.

[108]  W. Flintoff,et al.  Selection of wild-type revertants from methotrexate-resistant cells containing an altered dihydrofolate reductase , 1980, Somatic cell genetics.

[109]  J R Bertino,et al.  5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[110]  S. Howell,et al.  Thymidine requirements for the rescue of patients treated with high-dose methotrexate. , 1980, Cancer research.

[111]  F. Sirotnak,et al.  Extracellular recovery of methotrexate-polyglutamates following efflux from L1210 leukemia cells. , 1980, Biochemical pharmacology.

[112]  C. R. Pinkerton,et al.  Enterotoxic effect of methotrexate: does it influence the drug's absorption in children with acute lymphoblastic leukaemia? , 1981, British medical journal.

[113]  S. Howell,et al.  Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells. , 1981, Journal of the National Cancer Institute.

[114]  V. Devita,et al.  High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. , 1981, Cancer research.

[115]  R. Weichselbaum,et al.  Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate‐leucovorin in patients with advanced squamous carcinoma of the head and neck: A safe new effective regimen , 1981, Cancer.

[116]  D. Rosenblatt,et al.  Inhibition of methotrexate polyglutamate accumulation in cultured human cells. , 1981, Molecular pharmacology.

[117]  A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer , 1981, Cancer.

[118]  J. Galivan.  5-Methyltetrahydrofolate transport by hepatoma cells and methotrexate-resistant sublines in culture. , 1981, Cancer research.

[119]  A. Craft,et al.  Methotrexate absorption in children with acute lymphoblastic leukemia. , 1981, Cancer treatment reports.

[120]  E. Frenkel,et al.  Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. , 1981, Annals of internal medicine.

[121]  F. Sirotnak,et al.  Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux. , 1981, Cancer research.

[122]  H. Moss,et al.  The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia. , 1981, The American journal of medicine.

[123]  I. Taylor,et al.  Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry. , 1981, Cancer research.

[124]  S. Howell,et al.  Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. , 1981, The Journal of clinical investigation.

[125]  F. Sirotnak,et al.  Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. , 1981, Cancer research.

[126]  R. Schilsky,et al.  High-pressure liquid chromatography analysis of methotrexate polyglutamates in cultured human breast cancer cells. , 1981, Biochemical pharmacology.

[127]  J. Mulder,et al.  5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling. , 1981, European journal of cancer & clinical oncology.

[128]  R. Donehower,et al.  Competitive protein binding assay of methotrexate. , 1975, Methods in enzymology.